DT03 Rec'd PCT/PTO 1 0 JAN 2005

ORM P	FO-1390 -2000)	0 (Modified) U.S. DEPARTMENT OF COM	ATTORNEY'S DOCKET NUMBER					
11	TR	ANSMITTAL LETTER T	PF4879USW					
		DESIGNATED/ELECTE	U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR					
		CONCERNING A FILING	10/520754					
NTER		IONAL APPLICATION NO. PCT/EP03/07615	INTERNATIONAL FILING DATE July 11, 2003	PRIORITY DATE CLAIMED July 12, 2002				
	OF IN	VENTION						
	Aryl Piperidine Derivatives And Use Thereof To Reduce Elevated Levels of LDL-Cholesterol							
APPLI	CANT	r(s) FOR DO/EO/US	MAITDE Dames A. I					
BOU.	ıLL(OT, Anne, Marie, Jeanne; DU	OVIALI RE, Dernard, Andre					
A =	10=-1	growith cubraits to the II	tes Designated/Elected Office (DO/EO/US) the	following items and other information:				
				and and and anatom				
1.	Ø		ems concerning a filing under 35 U.S.C. 371. LIENT submission of items concerning a filing	z under 35 U.S.C. 371				
2.	X		UENT submission of items concerning a filing in national examination procedures (35 U.S.C.	g under 35 U.S.C. 371. 371(f)). The submission must include items (5),				
3.	☒	(6), (9) and (24) indicated below.	•	•				
4.	Ø		expiration of 19 months from the priority date ((Article 31).				
5.	×		ication as filed (35 U.S.C. 371 (c) (2))	Seed Dec. 2				
			ired only if not communicated by the Internati	rional Bureau).				
			by the International Bureau.	uing Office (PO/LIS)				
	_		pplication was filed in the United States Received					
6.			of the International Application as filed (35 U.	.5.0. 5/1(0)(4)).				
		a. is attached hereto.	mitted under 35 H S C 154/3//4)					
-	IC71	-	omitted under 35 U.S.C. 154(d)(4). International Application under PCT Article 1	19 (35 U.S.C. 371 (c)(3))				
7.	Ø		International Application under PCT Article I uired only if not communicated by the Internation					
			uired only it not communicated by the interna- ed by the International Bureau.					
			owever, the time limit for making such amendn	nents has NOT expired.				
		d. A have not been made; no						
8.			of the amendments to the claims under PCT A	rticle 19 (35 U.S.C. 371(c)(3)).				
9.	⊠	An oath or declaration of the inve						
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).						
11.	Ø	A copy of the International Prelin	minary Examination Report (PCT/IPEA/409).					
12.	Ø	A copy of the International Searc		••				
Ite	ems 1	3 to 20 below concern document	(s) or information included:					
13.	×	An Information Disclosure State	ement under 37 CFR 1.97 and 1.98.					
14.		An assignment document for reco	ording. A separate cover sheet in compliance	with 37 CFR 3.28 and 3.31 is included.				
15.	×	A FIRST preliminary amendment.						
16.		A SECOND or SUBSEQUENT preliminary amendment.						
17.		A substitute specification.						
18.		A change of power of attorney and/or address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.						
19.								
20.		A second copy of the published international application under 35 U.S.C. 154(d)(4).						
21.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).						
22. 23.	⊠ ⊠	Express Mail Label No. <u>EV</u> Other items or information:	<u> </u>					
٤٥.	(J)							
		a) PCT Cover Page b) PCT Request						

U.S. APPLICATION NO. (IE KNOWN-SEE-37 CFR INTERNATIONAL APPLICATION NO. PCT/EP03/07615					ATTORNEY'S DOCKET NUMBER PF4879USW				
24.	The	e following fees are submitted:.				CAI	CULATIONS	PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO									
Ճ	Internati	onal preliminary examination fee (37 CFR 1.482) not paid to							
	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$770.00								
	- CONTRACTOR OF								
	ENTER APPROPRIATE BASIC FEE AMOUNT =								
Surcha month	arge of \$1 s from the	30.00 for furnishing the oath or declar earliest claimed priority date (37 CF	ration later than R 1.492 (e)).	☐ 20	0		\$0.00		
CL	AIMS	NUMBER FILED	NUMBER EXTR	A	RATE				
Total o	laims	13 - 20 =	0		x \$18.00		\$0.00		
Indepe	endent cla	ims 1 - 3 =	0		x \$86.00		\$0.00		
Multip	ole Depen	dent Claims (check if applicable).	100100	- I			\$0.00		
			ABOVE CALCU			_	\$920.00		
	Applicant educed by	claims small entity status. See 37 CFF y 1/2.	R 1.27. The fees indicate	ed above	e are		\$0.00		
				SUB'	TOTAL =		\$920.00		
Proces month	sing fee o	of \$130.00 for furnishing the English to earliest claimed priority date (37 CF	translation later than FR 1.492 (f)).	☐ 20	0 🗆 30 +		\$0.00		
	TOTAL NATIONAL FEE =								
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).							\$0.00		
	TOTAL FEES ENCLOSED =						\$920.00		
							unt to be: efunded	\$	
							charged	\$	
a.								e above fees.	
b.	\boxtimes	Please charge my Deposit Account No	o. <u>07-1392</u> in	the ame	ount of \$92	20.00	to cover in	le above fees.	
c.		The Director is hereby authorized to c to Deposit Account No. 07-1392		es which	n may be required,	or cre	dit any overpay	ment	
d.	The state of the s								
NOTI 1.137	NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
						1.			
SEND	SEND ALL CORRESPONDENCE TO:								
SIGNATURE									
_	.				Lorie Ann M	organ			
00047				NAME					
	Z.	3347			38,181				
1					REGISTRATIO	JN NC	JMBER		
•	· ·								
					10 San	200	<u>'></u>		
					22				

10/520754 DT15 Rec'd PCT/PTO 10 JAN 2005

CERTIFICATE OF	Docket No.							
Applicant(s): Bouillot et	al.		PF4879USW					
Serial No. To Be Assigned	Filing Date Concurrently Herewith	Examiner	Group Art Unit					
Aryl Pinerid	ine Derivatives and Use Thereof T	o Reduce Elevated Levels of	LDL-Cholesterol					
Invention: Aryl Piperidine Derivatives and Use Thereof To Reduce Elevated Levels of LDL-Cholesterol								
			·					
I hereby certify that the	e following correspondence:							
Turnital of Notiona	I Phase Application w/accompan	ving naners						
Transmittal of Nationa	Transmittal of National Phase Application w/accompanying papers							
		of correspondence)						
			to Addressee" service under 37					
CFR 1.10 in an envelo	ope addressed to: Commissioner	for Patents, P.O. Box 1450,	Alexandria, VA 22313-1450 on					
1/10/05 (Pate)								
		Valorio I	Dhilling					
Valerie L. Phillips (Typed or Printed Name of Person Mailing Correspondence) (Signature of Person Mailing Correspondence)								
		`	164147US					
		("Express Mail" Maili	<u>/</u>					
	4-		•					